Teachers Retirement System of The State of Kentucky continued to hold its stake in shares of Chemed Corp. (NYSE:CHE) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,200 shares of the company’s stock at the end of the first quarter. Teachers Retirement System of The State of Kentucky’s holdings in Chemed Corp. were worth $1,133,000 as of its most recent filing with the SEC.
A number of other hedge funds have also modified their holdings of CHE. BlackRock Inc. increased its position in shares of Chemed Corp. by 145,760.9% in the first quarter. BlackRock Inc. now owns 1,955,994 shares of the company’s stock worth $357,341,000 after buying an additional 1,954,653 shares during the period. Norges Bank acquired a new position in shares of Chemed Corp. during the fourth quarter worth about $38,052,000. Vanguard Group Inc. increased its position in shares of Chemed Corp. by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,795,773 shares of the company’s stock worth $328,070,000 after buying an additional 125,018 shares during the period. State Street Corp increased its position in shares of Chemed Corp. by 9.1% in the first quarter. State Street Corp now owns 445,367 shares of the company’s stock worth $81,370,000 after buying an additional 37,085 shares during the period. Finally, Oppenheimer Asset Management Inc. acquired a new position in shares of Chemed Corp. during the first quarter worth about $4,445,000. Institutional investors own 98.33% of the company’s stock.
Chemed Corp. (CHE) traded down 0.09% on Friday, reaching $192.01. The company’s stock had a trading volume of 84,229 shares. Chemed Corp. has a 52-week low of $130.05 and a 52-week high of $216.01. The firm has a market capitalization of $3.07 billion, a P/E ratio of 47.63 and a beta of 1.14. The firm has a 50-day moving average price of $201.85 and a 200 day moving average price of $191.74.
Chemed Corp. (NYSE:CHE) last released its quarterly earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.89 by $0.26. Chemed Corp. had a return on equity of 26.18% and a net margin of 4.16%. The firm had revenue of $415.06 million for the quarter, compared to the consensus estimate of $407.56 million. During the same quarter last year, the business posted $1.80 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. Equities analysts anticipate that Chemed Corp. will post $8.20 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Monday, August 14th will be paid a $0.28 dividend. This is an increase from Chemed Corp.’s previous quarterly dividend of $0.26. The ex-dividend date of this dividend is Thursday, August 10th. This represents a $1.12 annualized dividend and a dividend yield of 0.58%. Chemed Corp.’s dividend payout ratio (DPR) is currently 26.07%.
TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/08/11/teachers-retirement-system-of-the-state-of-kentucky-continues-to-hold-stake-in-chemed-corp-nyseche-updated-updated-updated.html.
Several equities research analysts have recently weighed in on CHE shares. BidaskClub downgraded Chemed Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Royal Bank Of Canada reissued a “hold” rating and issued a $209.00 price objective on shares of Chemed Corp. in a report on Monday, July 31st. TheStreet cut Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded Chemed Corp. from a “hold” rating to a “buy” rating and set a $226.00 price target for the company in a research note on Friday, July 28th. Finally, Oppenheimer Holdings, Inc. upped their price target on Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a research note on Thursday, July 27th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $218.33.
In other news, Director George J. Walsh III purchased 1,000 shares of the company’s stock in a transaction on Monday, June 26th. The shares were purchased at an average price of $204.56 per share, with a total value of $204,560.00. Following the purchase, the director now directly owns 7,908 shares of the company’s stock, valued at approximately $1,617,660.48. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Kevin J. Mcnamara sold 15,000 shares of Chemed Corp. stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $201.16, for a total value of $3,017,400.00. Following the completion of the sale, the insider now directly owns 173,801 shares in the company, valued at approximately $34,961,809.16. The disclosure for this sale can be found here. Company insiders own 5.32% of the company’s stock.
Chemed Corp. Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
What are top analysts saying about Chemed Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemed Corp. and related companies.